REFERENCES
- Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count re-sponse to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13(6):F35–43.
- British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2 (4):276–313.
- DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective stud-ies using a standardized data analysis plan. Antiviral Ther. 2000;5(1):41–48.
- Gulick RM, Hu XJ, Fiscus SA, et al. Randomised study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in Human Immunodeficiency Virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359. J Infect Dis. 2000;182:1375–1384.
- Hammer S, Squires K, Degruttola V, et al. Randomised trial of ABC, and nelfinavir in combination with efavirenz and adefovir dipivoxil as salvage therapy inpatients with virologic failure receiving indinavir. In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; Chicago; Jan. 31-Feb. 4, 1999. Abstract 490.
- Shulman NS, Zolopa RA, Passaro DJ, et al. Efavirenz and adefovir dipivoxil based salvage therapy in highly treat-ment experienced patients: clinical and genotypic predic-tors of virologic response. J AIDS. 2000;23:221–226.
- Hammer SM, Vaida F, Bennett KK, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: a randomised trial. JAMA. 2002;288(2):239–241.
- Carmena J, Ricart C, Jordan M, Vicente R, Perez C, Alcaraz MJ, Leon P. Observational protease inhibitor sal-vage study, using efavirenz plus two new nucleoside re-verse transcriptase inhibitors. In: Program and abstracts of the Seventh Annual Meeting of the British HIV Association; April 2001; Brighton. Abstract P33.
- Albrecht MA, Bosch RJ, Liou SH, Katzenstein D. ACTG 364: efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new NRTIs in nucleoside experienced subjects: week 144 results. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 425–W.
- Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs nevirapine comparison): a random-ised, open label study in HIV infected naïve individuals. HIV Clin Trials. 2002 ; 3(3):186–194.
- Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly anti-retroviral-experienced patients. AIDS. 200115: 2385–2395.
- Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in anti-retroviral-naïve patients: a cohort study. AIDS. 2002;16:53–61.
- Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, et al. Virologic and immunologic response to regimens contain-ing nevirapine or efavirenz in combination with 2 nucleo-side analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis. 2002; 185(8):1062–1069.
- Keiser P, Nassar N, White C, Koen G, Moreno S. Cohort study shows treatment advantage across many risk factors for efavirenz vs. nevirapine-containing regimens in treat-ment-naïve HIV-1 infected individuals. In: Late breaker pro-gram of the Eighth European Conference on Clinical As-pects and Treatment of HIV Infection; 2001; Athens, Greece.
- Fischl M, Greenberg S, Clumeck N, et al. Ziagen combined with 3TC and ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naïve subjects (CNAA 3003). In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infec-tions; 1999; Chicago. Abstract 19.